Our results identify snoRNAs, particularly <i>SNORD105B</i>, as potential novel markers of CKD risk and SGLT2 inhibitor response in type 2 diabetes, revealing an unexplored sncRNA axis and providing a foundation for future functional studies into their mechanistic role in CKD progression. This evidence concerns the gene SLC5A2 and chronic kidney disease.